Distinct Immunometabolic Alterations in Psoriasis and Atopic Dermatitis: Insights into Two Inflammatory Skin Conditions

Category	Detail
Condition	Psoriasis and Atopic Dermatitis
Key Mechanisms	Differential metabolic pathways in immune cells and keratinocytes; Th17/IL-17 vs. Th2/IL-4-IL-13 profiles.
Target Population	Individuals with chronic inflammatory skin diseases.
Care Setting	Clinical practice for dermatological conditions.

Psoriasis is characterized by glycolytic metabolism and IL-17/IL-23 axis involvement.
Atopic dermatitis features impaired epidermal ceramide synthesis and Th2-dominant immune response.
Both conditions exhibit distinct metabolic profiles influencing treatment approaches.
Biologics targeting IL-17 and IL-23 are effective for psoriasis; dupilumab and JAK inhibitors are used for AD.
Metabolism-targeted drugs like metformin and statins show potential therapeutic benefits.

Diagnosis of psoriasis involves identifying characteristic lesions and histopathological features.
Atopic dermatitis diagnosis is based on clinical presentation and immunological markers.

Psoriasis management includes biologics targeting IL-17 and IL-23.
Atopic dermatitis management involves dupilumab, tralokinumab, and JAK inhibitors.

Monitor psoriasis for systemic complications such as cardiovascular and metabolic syndrome.
Monitor atopic dermatitis for skin barrier integrity and pruritus severity.

Psoriasis is associated with increased risk of joint and cardiovascular diseases.
Atopic dermatitis may lead to secondary infections due to skin barrier disruption.

Patients with psoriasis and atopic dermatitis.

Metabolism-targeted therapies may provide new avenues for personalized treatment.

Utilize a unified metabolic immunology framework for understanding psoriasis and AD.
Consider metabolic profiles when selecting treatment options for patients.

Clinical Scorecard: Distinct Immunometabolic Alterations in Psoriasis and Atopic Dermatitis: Insights into Two Inflammatory Skin Conditions